At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
NRT6003 Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study on the Safety and Effectiveness of NRT6003 Injection in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Chengdu New Radiomedicine Technology Co. LTD.·interventional·Posted Mar 15, 2024·Updated Feb 3, 2026
In Brief
A Phase 1 clinical trial evaluating NRT6003 Injection for Unresectable Hepatocellular Carcinoma. Completed, enrolled 40 participants across 10 sites.
Detailed Summary
The goal of this clinical trial is to evaluate the safety and efficacy of NRT6003 Injection in patients with unresectable HCC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUnresectable Hepatocellular Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
Enrollment StartAug 2023
First PostedMar 2024
Primary CompletionJun 2025
TodayJul 2026
First PostedMar 15, 2024
Enrollment StartAug 8, 2023
Primary CompletionJun 10, 2025
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 2.3 years ago
Interventions
NRT6003 Injectiondrug
Selective internal radiation therapy (SIRT) with TareSphere